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we propose to adapt the TG 119 to VMAT treatments using a 
different 3D cylindrical dosimetric phantom. 
Materials and Methods: TG119 structures were superimposed 
on the CT images of a cylindrical PMMA phantom surrounding 
two orthogonal matrices with 1069 total diodes (Delta4 - 
Scandidos, SWE). TG119 tests were thus calculated and 
optimized using Monaco 3.3 (Elekta, SWE) and, recently, 
recalculated with the new version 5, for 6 and 10 MV photon 
beams, for VMAT techniques, following all plan goals 
proposed by TG119. Delta4 phantom was used in order to 
carry out a comparison between measured and planned 3D 
absolute dose distributions. A 3%, 3mm gamma test (global 
and local) with a 10% threshold (defined by the isodose line 
representing 10% of maximum dose) was used for plans 
analysis and Confidence Limits (CL = |100 – mean| +1.96 * SD) 
were also generated. 
Results/ Goals proposed in TG119 were mostly satisfied for 
each plan and technique except for the Multi Target, where 
the dose at 99% of the volume (D99 goal) to the central 
volume was not achieved. The range of global gamma passing 
points was 98.4% – 99.7% of total compared points, with a 
mean percentage value of 99.1 ± 0.5% for all photon energies 
and all plans thus generating a confidence limit of 2.3% and 
1.5% for 6 and 10MV photons beam respectively. The range of 
local gamma passing points was 96.2% – 98.9%, with a mean 
percentage value of 97.7 ± 1.1%, now generating a 
confidence limit of 5.4% and 2.6% for 6 and 10MV 
respectively. 
Conclusions: TG119 structures and plans were found to be 
adaptable to VMAT treatments and Delta4 phantom, enabling 
a more exhaustive evaluation procedure, although this 
solution is also more expensive than the TG119 one. The use 
of a local gamma stresses all outcomes thus highlighting any 
local critical area. CLs allow to generate 'in house' reference 
values to evaluate the overall result of the entire dosimetric 
process involved in volumetric treatments. Even in the worst 
case CLs are well lower than the reference one proposed in 
TG119 (12.4%). Concluding, even if not designed for IMRT, 
our results showed that TG119 can be a practical 
commissioning procedure for VMAT therapy too. 
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Purpose/Objective: An EPID-based in-vivo dosimetry method 
for 3D-conformal radiotherapy (DISO) and widely used in 
several Italian Centers has now been expanded to VMAT 
technique. In this study we prospectively evaluated this 
transit dosimetry algorithm for complex VMAT treatments 
and analyzed the issues and challenges for a large-scale 
adoption in clinical routine. 
Materials and Methods/ 20 consecutive patients with head-
and-neck tumors and treated with SIB-VMAT using Elekta 
Precise linacs were enrolled. All plans were generated with 
Oncentra Masterplan TPS and optimized in dual-arc modality. 
Three targets were simultaneously irradiated over 30 daily 
fractions. Doses of 70.5, 60.0 Gy and 55.5 Gy were prescribed 
to primary tumor, high-risk lymph nodal region and low-risk 
nodal region, respectively. All patients passed pre-treatment 
3%/3mm γ-analysis verification with γ pass-rate of more than 
95%. In-vivo tests were evaluate by means of (i) ratio R 
between daily in-vivo isocenter dose and planned dose and 
(ii) γ-analysis between EPID integral portal images in terms of 
percentage of points with γ-value smaller than one (γ%) and 
mean γ-values (γmean), using a global 3%-3mm criteria. Alert 
criteria of ±5% for R ratio, γ%>90% and γmean<0.67 were 
chosen, the last two in order to accept only 10% of the values 
to exceed 3%/3mm and an average discrepancy of the order 
of 2%/2mm, respectively. 
Results: A total of 368 transit EPID images, two images for 
each VMAT plan, were acquired during the treatment 
fractions of 20 patients. 28 images (7.6%) were removed from 
analysis for image deterioration and/or electronic acquisition 
failures. The overall mean R ratio was equal to 1.000 ± 0.026 
(1SD), with 92.1% of tests within ±5%. The 2D portal images 
γ-analysis show an overall γmean of 0.44±0.18 with 90.0% of 
tests within alert criteria, and a mean γ% equal to 91.9±5.7% 
with 75.8% of tests within alert criteria. 54 (16%) 2D portal γ-
tests showing lower values of γ pass-rate were associated 
with dose discrepancies. In particular, clinical relevant 
discrepancies were observed in four patients: a set-up error 
was detected at the beginning of treatment for one patient 
and three patients showed major anatomical variations 
(weight loss/tumor shrinkage) in the second half of 
treatment. The results are supplied in quasi real-time, with 
in-vivo tests performed and displayed after only 1 minute 
from the end of arc delivery. 
Conclusions: Our EPID-based in-vivo dosimetry algorithm 
provided a fast and accurate procedure for VMAT delivery 
verification in clinical routine. An efficient procedure allow 
to obtain the results within 1 minute after each arc delivery. 
This procedure was able to detect when delivery was 
inconsistent with the original plans, allowing physics and 
medical staff to promptly act in case of major deviations 
between measured and planned dose.  
 
EP-1560   
A national QA audit for IMRT and VMAT 
E. Seravalli1, A.C. Houweling2, M.P.R. Van Gellekom3, J. 
Kaas4, M. Kuik5, E. Loeff6, T.A. Raaben7, J.A. De Pooter8, 
J.H.W. De Vries1, J.B. Van de Kamer4 
1UMC Utrecht, Department of Radiation Oncology, Utrecht, 
The Netherlands  
2Academic Medical Center, Department of Radiation 
Oncology, Amsterdam, The Netherlands  
3Arnhems Radiotherapeutisch Instituut, Department of 
Radiotherapy, Arnhem, The Netherlands  
